Last reviewed · How we verify

NCT05258812

Cytopenias in Hospitalized Patients of Corona Virus Infection(COVID-19) During First and Other Waves

Completed Last updated 28 February 2022
What this trial tests

trial in Corona Virus Infection in 202 participants. Completed in 30 June 2021.

Timeline
1 May 2020
Primary endpoint
30 June 2021
30 June 2021

Quick facts

Lead sponsorFatima Memorial Hospital
StatusCompleted
Study typeOBSERVATIONAL
Enrollment202
Start date1 May 2020
Primary completion30 June 2021
Estimated completion30 June 2021
Sites1 location across Pakistan

Conditions studied

Sponsor

Fatima Memorial Hospital

Who can join

Adults 10 to 95, any sex, with Corona Virus Infection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Demographic, Clinical and laboratory data as well as outcome of total 202 COVID-19 patients who were Polymerase Chain Reaction (PCR) positive and admitted in Fatima memorial Hospital, Lahore, Pakistan, was collected during first and other waves. Data of First wave is from May 2020 to July 2020, second wave from early November to Mid December 2020 and third wave from Mid march to June 2021. Investigator analyzed the data on basis of Systemic immune inflammatory index (SII) as well hematological parameters of First Wave were compared to other waves of COVID-19.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Corona Virus Infection

Currently open trials in the same condition.

Other Fatima Memorial Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05258812.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing